Scienta Lab Information

Scienta is a deeptech company advancing translational research in immunology. Scienta develops EVA, the first AI foundation model purpose-built for translational prediction in immune-mediated diseases. EVA addresses a critical challenge in pharma R&D: the preclinical–clinical gap, where fewer than 10% of immune drug programs translate successfully to humans. Built on more than 3 billion multimodal data points across 30 diseases and 70 tissues, EVA uses a biology-first architecture designed to reason like an immunologist. It converts early experimental signals into predicted patient outcomes, with explainable outputs such as pathway-level activity and mechanism-linked biomarkers. Scienta’s approach is scientifically validated and supported by 18 peer-reviewed publications and 2 patents. Based at BioLabs Hôtel-Dieu in Paris, Scienta is backed by leading investors, selected among Station F’s Future 40, and named a laureate of the 2025 EIC Accelerator.